Skip to main navigation
  • About Us
    • Our Company
    • Management & Board
    • Who We Help
  • Our Approach
    • Toll-Like Receptor Activation
    • Publications & Presentations
  • Areas of Focus
    • Immuno-Oncology
    • Pipeline & Programs
  • Investor Relations
  • Investor Relations
    • Investors and Media
    • Annual Meeting Materials
    • Analyst Coverage
    • Press Releases
    • Investor Events
    • Corporate Governance
    • Stock Information
    • Financial Reports
    • SEC Filings
    • Investor Information
    • E-mail Alerts
  • Join Us
×

Investors

MainNavMenu

  • Investors and Media
  • Annual Meeting Materials
  • Analyst Coverage
  • Press Releases
  • Investor Events
  • Corporate Governance
  • Stock Information
    • Historical Price Lookup
    • Investment Calculator
    • Stock Chart
    • Stock Quote
  • SEC Filings
  • Investor Information
  • E-mail Alerts

Contact us

Please direct all questions regarding Idera to:

Idera Pharmaceuticals, Inc.
505 Eagleview Blvd, Suite 212
Exton, PA 19341

call (484) 348-1600
fax (484) 348-1670

info@iderapharma.com

Investor Tools

Print Page
RSS Feeds
E-mail Alerts

Earnings Estimates

AnalystMenu

  • Analyst Coverage
  • Earnings Estimates
Glossary

Analyst Ratings

Mean Recommendation:

3.00

Sell

Strong Buy

Copyright Refinitiv

MainNavMenu

  • Investors and Media
  • Annual Meeting Materials
  • Analyst Coverage
  • Press Releases
  • Investor Events
  • Corporate Governance
  • Stock Information
    • Historical Price Lookup
    • Investment Calculator
    • Stock Chart
    • Stock Quote
  • SEC Filings
  • Investor Information
  • E-mail Alerts

Contact us

Please direct all questions regarding Idera to:

Idera Pharmaceuticals, Inc.
505 Eagleview Blvd, Suite 212
Exton, PA 19341

call (484) 348-1600
fax (484) 348-1670

info@iderapharma.com

Investor Tools

Print Page
RSS Feeds
E-mail Alerts

© 2022 Idera. All rights reserved.

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Share